Next-generation Cancer Diagnostics
About Next-generation Cancer Diagnostics
Accelerating earlier cancer detection and precision medicine through multi-omics, AI and next-generation diagnostics
The Next Generation Cancer Diagnostics (NG-Dx) programme is bringing together industry, clinicians, researchers, regulatory bodies, patient groups and technology partners to overcome the barriers preventing earlier cancer detection and faster adoption of innovative diagnostic technologies.
Backed by £5 million funding from the UK Government’s Office for Life Sciences, the programme is creating the collaborations, evidence and frameworks needed to translate breakthrough innovations into clinical practice.
Our collaborative workstreams
The programme focuses on three priority workstreams that were identified through consultation with experts from industry, healthcare, academia and government, and further refined during the inaugural Next Generation Cancer Diagnostics workshop in June 2026. Together, they address the key barriers limiting the development and adoption of innovative cancer diagnostics and provide the greatest opportunity to accelerate earlier diagnosis and improve patient outcomes.
- Cell-free DNA: Improving sample preparation, standardisation and analytical workflows to increase confidence in liquid biopsy technologies.
- Proteomics: Developing robust, reproducible proteomic workflows that support earlier disease detection and precision medicine.
- Multi-omics Data Architecture: Creating interoperable, AI-enabled data frameworks that integrate genomic, proteomic and clinical information to support better diagnostic decision making.
Who should get involved?
The programme brings together organisations from across the cancer diagnostics ecosystem to tackle shared challenges and accelerate innovation. Whether you’re a diagnostics developer, pharmaceutical or biotechnology company, AI or digital health provider, NHS organisation, clinician, SME, academic researcher or patient representative, you’ll have the opportunity to collaborate with leading partners, shape future standards, validate new technologies, access multidisciplinary expertise and help accelerate the adoption of next-generation cancer diagnostics to improve patient outcomes.
How to get involved
Whether you’re developing diagnostics, applying AI, generating clinical evidence or looking to collaborate, we’d like to hear from you. To explore collaborative R&D opportunities, contact Pari Datta, Head of Technology Strategy, CPI.
We’re also hosting a follow-up workshop on 26 – 27 November 2026 in central London. Register your interest in attending by completing the form below.